L J Burns - JoVE Visualize

Showing results (31-40 of 46) with videos related to

Pageof 5

Sort By:

Cancer|March 1, 1993

Etoposide in combination as first-line chemotherapy for advanced Hodgkin disease. A Cancer and Leukemia Group B studyJ J Kirshner, J R Anderson, B Parker, et al.

Journal of Immunological Methods|October 16, 1996

Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignanciesD A Vallera, L J Burns, A E Frankel, et al.

Bone Marrow Transplantation|September 23, 2008

Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphomaV Bachanova, C G Brunstein, L J Burns, et al.

Bone Marrow Transplantation|January 26, 2006

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT)J D Rizzo, J R Wingard, A Tichelli, et al.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 1, 1997

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activityJ S Miller, J Tessmer-Tuck, B A Pierson, et al.

Bone Marrow Transplantation|October 24, 2000

Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantationJ D Lickliter, P B McGlave, T E DeFor, et al.

Bone Marrow Transplantation|August 30, 2008

High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantationN S Majhail, M E Flowers, K K Ness, et al.

Bone Marrow Transplantation|January 16, 2007

Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trialM Markova, J N Barker, J S Miller, et al.

Bone Marrow Transplantation|July 3, 2003

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trialL J Burns, D J Weisdorf, T E DeFor, et al.

Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003

Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude miceD A Vallera, M Elson, M W Brechbiel, et al.

Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:

Pageof 5

Cancer|March 1, 1993

Etoposide in combination as first-line chemotherapy for advanced Hodgkin disease. A Cancer and Leukemia Group B studyJ J Kirshner, J R Anderson, B Parker, et al.

Journal of Immunological Methods|October 16, 1996

Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignanciesD A Vallera, L J Burns, A E Frankel, et al.

Bone Marrow Transplantation|September 23, 2008

Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphomaV Bachanova, C G Brunstein, L J Burns, et al.

Bone Marrow Transplantation|January 26, 2006

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT)J D Rizzo, J R Wingard, A Tichelli, et al.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 1, 1997

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activityJ S Miller, J Tessmer-Tuck, B A Pierson, et al.

Bone Marrow Transplantation|October 24, 2000

Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantationJ D Lickliter, P B McGlave, T E DeFor, et al.

Bone Marrow Transplantation|August 30, 2008

High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantationN S Majhail, M E Flowers, K K Ness, et al.

Bone Marrow Transplantation|January 16, 2007

Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trialM Markova, J N Barker, J S Miller, et al.

Bone Marrow Transplantation|July 3, 2003

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trialL J Burns, D J Weisdorf, T E DeFor, et al.

Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003

Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude miceD A Vallera, M Elson, M W Brechbiel, et al.

Pageof 5